



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-713-i9)

#31/1656
PATENT

JAN 29 2002
TECH CENTER 1600/2300

In the Application of:

Mirkin *et al.*

Examiner: J. Riley

Serial No. 09/973,638

Group Art Unit: 1656

Filed: October 10, 2001

For: Nanoparticles Having Oligonucleotides
Attached Thereto and Uses Therefor

Confirmation No.: 7336

Box SEQUENCE

Commissioner for Patents
Washington, D.C. 20231

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached

- a. Response to Notice to Comply dated December 3, 2001
- b. Copy of the Notice to Comply
- c. Sequence Listing (paper and computer readable form on 3.5" diskette)
- d. Return Receipt Postcard

2. With respect to additional fees:

- ☒ A. No additional fee is required.
- ☐ B. Attached is a check in the amount of \$_____.

3. General Authorization: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Box SEQUENCE, Commissioner for Patents, Washington, D.C. 20231 on this 3 day of January, 2002.

Date: 1/3/02

By [Signature]

Emily Miao
Reg. No. 35,285

BEST AVAILABLE COPY



#3

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-713-i9)

In the Application of:

Mirkin *et al.*

Serial No. 09/973,638

Filed: October 10, 2001

For: Nanoparticles Having Oligonucleotides
Attached Thereto and Uses Therefor

Examiner: J. Riley

Group Art Unit: 1656

Confirmation No.: 7336

TECH CENTER 1600/2900

JAN 29 2002

RECEIVED

RESPONSE TO NOTICE TO COMPLY

Box SEQUENCE
Commissioner for Patents
Washington, D.C. 20231

Sir:

This is in response to the Notice to Comply mailed December 3, 2001. Attached is a paper copy of a Sequence Listing and 3.5" diskette containing a computer readable copy of the Sequence Listing in accordance with 37 C.F.R. § 1.821(e). In accordance with 37 C.F.R. §§ 1.821-1.825, the computer readable copy is identical to the paper copy filed with the disclosure of the application and the attached Sequence Listing. No new matter has been added to the application as a result of this submission.


Prompt consideration and entry of this response is respectfully requested.

Respectfully submitted,

Date: 1/3/02

By: 

Emily Miao
Reg. No. 35,285



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/973,638	10/10/2001	Chad A. Mirkin	00-713-i9

Emily Miao
McDonnell Boehnen Hulbert & Berghoff
32nd Floor
300 S. Wacker Drive
Chicago, IL 60606

RECEIVED
JAN 2 9 2002
TECH CENTER 1600/2900

CONFIRMATION NO. 7336

FORMALITIES LETTER



OC000000007149094

Date Mailed: 12/03/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).


- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

BEST AVAILABLE COPY



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

BEST AVAILABLE COPY